TardiMed Sciences LLC - 02 Sep 2021 Form 4 Insider Report for Timber Pharmaceuticals, Inc.

Reporting relationship: 10%+ Owner
Issuer ticker: N/A
Reported as of: 02 Sep 2021
Net transaction value: -$210,960
SEC form: 4
Accepted by SEC: 02 Sep 2021, 19:11:23 UTC
Prior SEC filing: 01 Sep 2021
Next SEC filing: 12 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael Derby, Managing Partner of TardiMed Sciences LLC

Key filing fact

TardiMed Sciences LLC filed Form 4 for Timber Pharmaceuticals, Inc. on 02 Sep 2021.

Key facts

This page summarizes TardiMed Sciences LLC's Form 4 filing for Timber Pharmaceuticals, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Sep 2021, 19:11.

Change

Previous filing in this sequence was filed on 01 Sep 2021.
Current net transaction value: -$210,960.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TMBR transaction

Common Stock, par value $0.001 per share

Sale

Transaction value: $210,960
Shares: -225,000
Change %: -6%
Price: $0.9376
Shares after: 3,508,567
Date: 02 Sep 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

TardiMed Sciences LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

The price represents the weighted average sales price for multiple transactions reported on this line. The prices of the transactions ranged from $0.9011 to $0.9971, inclusive. The reporting person undertakes to provide to Timber Pharmaceuticals, Inc. ("Timber"), any security holder of Timber, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.